DEVELOPMENT AND VALIDATION OF DIFFERENTIAL PULSE POLAROGRAPHIC ANALYSIS OF FENOFIBRATE IN PURE AND PHARMACEUTICAL DOSAGE FORMS USING DROPPING MERCURY ELECTRODE
DOI:
https://doi.org/10.22159/ijpps.2016v8i10.12762Keywords:
Differential pulse polarographic analysis, Fenofibrate, Pharmaceutical formulationsAbstract
Objective: An easy, fast, accurate and sensitive differential pulse polarographic analysis for determination of fenofibrate (FEN) in pure and pharmaceutical dosage forms using dropping mercury electrode (DME) was applied.
Methods: The method involves the electrochemical reduction of fenofibrate at DME by differential pulse polarographic analysis (DPPA). Different buffer solutions were used over a wide pH range (1.0–10.0). The best definition of the analytical signals was found in lithium perchlorate trihydrate buffer at pH 6.0 containing 24% (v/v) acetonitrile at-994 to-1025mV (versus Ag/AgCl).
Results: Under optimized conditions the peak current (Ip) is linear over the range 0.0361-3.608 μg/ml. The DPPA was used successfully for the determination of FEN in pure and pharmaceutical dosage forms. The relative standard deviation did not exceed 2.1% for the concentration of FEN 0.0361 μg/ml. Regression analysis showed a good correlation coefficient (R2= 0.9994) between Ip and concentration at the mentioned range. The limit of detection (LOD) and the limit of quantification (LOQ) was to be 0.0025 and 0.0076 μg/ml, respectively. The proposed method was validated for linearity, precision and accuracy, repeatability, sensitivity (LOD and LOQ), robustness and specificity with an average recovery of 99.8-100.6%.
Conclusion: The developed method is applicable for the determination of FEN in pure and different dosage forms with the assay of marketed formulations 99.8-104.0% and the results are in good agreement with those obtained by square-wave voltammetry (SWV) reference method.
Keywords: Differential pulse polarographic analysis, Fenofibrate, Pharmaceutical formulations
Downloads
References
- Martindale: The Extra Pharmacopoeia, The Complete Drug Reference (1999) 32nd Ed., K. Porfitt (Ed.), Royal Pharmaceutical Society, London, UK.
- Neil Maryadele JO, Merck Index. 2006;14:1743.
- Yardımcı C, Ozaltın N, Electrochemical studies and square-wave voltammetric determination of fenofibrate in pharmaceutical formulations. Anal Bional Chem 2004; 378:495-8.
- Sahoo DK, Sahu PK, Patro CS. New validated isocratic RP-HPLC method for assay of fenofibrate. Int J Pharm Pharm Sci 2014;6(2):169-72.
- Mohamed A. Korany, Ismail I. Hewala, Karim M. Abdel-Hay, Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and squarewave voltammetric techniques. J AOAC Int 2008; 91(5): 1051-8.
- Suresh Kumar GV, Rajendra Prasad Y. Development and Validation of Reversed-Phase HPLC Method for Simultaneous Estimation of Fenofibrate and Fenofibrate in Tablet Dosage Form. International Journal of PharmTech Research 2010; 2(3): 2016-21.
- Rupali H, Ravindra B, Manish K. RP-HPLC method for simultaneous estimation of atorvastatin calcium and fenofibrate in tablet dosage forms. journal of pharmacy research 2010; 3(10): 2400-01.
- Choudhari VP, Nikalje AP. Simultaneous Estimation of Atorvastatin, Ezetimibe and Fenofibrate in Pharmaceutical Formulation by RP-LC-PDA. Pharm Anal Acta. 2010; 1: 111.
- Krishna RG, Sonali SA, Prashant RR and Sudhir GW. Validated spectrophotometric determination of fenofibrate in formulation. Der Pharmacia Sinica 2010; 1(1): 173-178.
- Sevda RR, Ravetkar AS, Shirote PJ. UV Spectrophotometric estimation of fenofibrate calcium and fenofibrate in bulk drug and dosage form using simultaneous equation method. Int J Chem Tech Res 2011;3(2):629-35.
- Dhabale PN, Gharge DS. Simultaneous spectrophotometric estimation of atorvastatin and fenofibrate in bulk drug and dosage form by using simultaneous equation method. Int J Chem Tech Res 2010;2(1):325-8.
- ICH: Proceedings of the International Conference on Harmonization of Technical Requirement of Registration of Pharmaceuticals for Human Use (ICH Harmonized Tripartite Guidelines).